Lowering Drug Prices by Once Again Putting Americans First
Headline: Directs Federal Government to Cut Prescription Drug Prices Nationwide
What it does: Agencies must issue rules, reports, and recommendations to lower drug prices and reform Medicare, Medicaid, and importation programs.
- Targets reduction in Medicare Part D premiums and out-of-pocket drug costs.
- Requires health centers to offer insulin and epinephrine at discounted prices.
- Aims to speed approval of generics, biosimilars, and increase drug importation.
Summary
This order directs federal agencies to take multiple steps to lower prescription drug prices and increase competition. It requires new guidance and reforms for the Medicare drug negotiation program, seeks plans to reduce Medicare Part D premiums, and directs actions to speed approval of generics, expand drug importation, and improve Medicaid drug payment rules.
The order affects Medicare and Medicaid patients, health centers, employers, state programs, and pharmaceutical manufacturers, aiming to make medicines more affordable and to protect taxpayers from high drug spending.
Ask about this order
Ask questions about this executive order and its implications.
What agencies are affected by this order?
How does this order change existing policy?
What are the practical implications of this order?